Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
April 15, 1986CancerOpen Access

The role of recombinant interferon alfa-2a in the therapy of cutaneous t-cell lymphomas

View Full Paper
Ask AI
Bookmark
Share

Authors

Paul A. BunnPaul A. BunnAstraZeneca (United Kingdom)DIDaniel C. IhdeNaval Medical Research CommandKFKenneth A. FoonGynecologic Oncology Group

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Bunn et al. (1986) studied this question.

synapsesocial.com/papers/69d7c518f39344339dd181c0https://doi.org/10.1002/1097-0142(19860415)57:8+<1689::aid-cncr2820571311>3.0.co;2-m
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Recombinant Leukocyte A Interferon: An Active Agent in Advanced Cutaneous T-Cell Lymphomas1984 · 271 citations
  2. 2Interferons in the treatment of human cancer.1984 · 333 citations
  3. 3Acute Interstitial Nephritis with the Nephrotic Syndrome Following Recombinant Leukocyte A Interferon Therapy for Mycosis Fungoides1984 · 181 citations
  4. 4Follow-up observations on the effect of human leukocyte interferon in non-Hodgkin's lymphoma1981 · 121 citations
  5. 5Leukocyte Interferon-Induced Tumor Regression in Human Metastatic Breast Cancer, Multiple Myeloma, and Malignant Lymphoma1980 · 503 citations